Roche's Subcutaneous Ocrevus Rivals IV Formulation in Phase III MS Trial
The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.
Source: biospace.com